• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Invitation to the presentation of Calliditas's interim report January - June 2024

    8/5/24 1:19:00 AM ET
    $CALT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CALT alert in real time by email

    STOCKHOLM, Aug. 5, 2024 /PRNewswire/ -- Calliditas's interim report for the second quarter, April - June 2024 will be published in Swedish and English on Tuesday 13 August 2024 at 07.00 a.m. CET.

    A combined audio cast and telephone conference with the opportunity to ask questions will be held at 14.30 p.m. CET on the same day, with CEO Renée Aguiar-Lucander and CFO Fredrik Johansson, CMO Richard Philipson and President North America Maria Törnsén.

    The presentation will be given in English.

    Link to the webcast: 

    https://ir.financialhearings.com/calliditas-therapeutics-q2-report-2024

    To participate via conference call please register via this link:

    https://conference.financialhearings.com/teleconference/?id=50049712

    After registration, you will receive a phone number and a conference ID to log in to the conference call. Via the telephone conference, there is an opportunity to ask oral questions.

    For further information, please contact:

    Åsa Hillsten, Head of IR & Sustainability, Calliditas

    Tel.: +46 76 403 35 43, Email: [email protected]

    The information was sent for publication, through the agency of the contact persons set out above, on August 5, 2024 at 7:00 a.m. CET.

    This information was brought to you by Cision http://news.cision.com

    https://news.cision.com/calliditas-therapeutics/r/invitation-to-the-presentation-of-calliditas-s-interim-report-january---june-2024,c4019260

    The following files are available for download:

    https://mb.cision.com/Main/16574/4019260/2928380.pdf

    Invitation to the presentation of Calliditas_Q2 2024 ENG

     

    Cision View original content:https://www.prnewswire.com/news-releases/invitation-to-the-presentation-of-calliditass-interim-report-january--june-2024-302214085.html

    SOURCE Calliditas Therapeutics

    Get the next $CALT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CALT

    DatePrice TargetRatingAnalyst
    6/20/2023$60.00Buy
    H.C. Wainwright
    3/1/2023$18.00Neutral
    Guggenheim
    12/20/2021$52.00 → $62.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CALT
    SEC Filings

    See more
    • SEC Form 15F-12B filed by Calliditas Therapeutics AB

      15F-12B - Calliditas Therapeutics AB (0001795579) (Filer)

      9/23/24 4:44:35 PM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Calliditas Therapeutics AB

      25-NSE - Calliditas Therapeutics AB (0001795579) (Subject)

      9/20/24 4:45:11 PM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC TO-T/A filed by Calliditas Therapeutics AB

      SC TO-T/A - Calliditas Therapeutics AB (0001795579) (Subject)

      9/18/24 9:02:28 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care